Activity Overview
This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of generalized myasthenia gravis (gMG), with a forward-looking perspective on how new and novel agents might impact clinical practice. The essentials of disease classification, clinical trial data, and current and emerging treatment strategies will be presented.
Target Audience
This educational activity is directed towards neurologists, physician assistants, nurse practitioners, and other health care professionals involved in the treatment of gMG.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Outline the role of B cells in the pathophysiology of gMG
- Assess emerging data on targeted therapies for generalized myasthenia gravis
James F. Howard Jr, MD, FAAN
Professor of
Neurology, Medicine, and Allied Health
UNC Chapel School of Medicine
The University of North Carolina at Chapel Hill
Chapel Hill, NC
Disclosures: Grant Research Support: Alexion Pharmaceuticals, Argenx, Biologix Pharma, Millennium Pharmaceuticals; Other: Alexion Pharmaceuticals, Argenx, Biologix Pharma
Tuan Vu, MD
Professor,
Department of Neurology
University of South Florida
Tampa, FL
Disclosures: Grant/Research Support/Honoraria: Alexion Pharmaceuticals, Allergan.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
This accredited activity has been developed in accordance with applicable accreditation standards to ensure balance, independence, objectivity, and scientific rigor. Faculty were instructed to use generic names where possible and to base recommendations on the best available evidence.
In the context of clinical discussion, proprietary product names may be mentioned. Such references are made for educational purposes only and do not constitute endorsement of any commercial product or service.
Learners are encouraged to independently evaluate the information presented and apply their own clinical judgment when considering patient care decisions.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.